LUCY vs PRPH vs VSCO vs QDEL vs HOLX

For growth investors, Innovative Eyewear, Inc.

(LUCY) is the stronger pick with 42. 0% revenue growth year-over-year, versus -84. 7% for ProPhase Labs, Inc. (PRPH). Victoria's Secret & Co. (VSCO) offers the better valuation at 23. 3x trailing P/E (17. 4x forward), making it the more compelling value choice. Analysts rate Victoria's Secret & Co. (VSCO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Victoria's Secret & Co.

(VSCO) is the cheapest at 23. 3x versus Hologic, Inc. at 30. 5x. On forward P/E, QuidelOrtho Corporation is actually cheaper at 6. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -99. 1% for Innovative Eyewear, Inc. (LUCY). Over 10 years, the gap is even starker: HOLX returned +124. 3% versus LUCY's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus QuidelOrtho Corporation's 2. 59β — meaning QDEL is approximately 530% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 4% for Victoria's Secret & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Innovative Eyewear, Inc.

(LUCY) is pulling ahead at 42. 0% versus -84. 7% for ProPhase Labs, Inc. (PRPH). On earnings-per-share growth, the picture is similar: Innovative Eyewear, Inc. grew EPS 59. 0% year-over-year, compared to -166. 3% for ProPhase Labs, Inc.. Over a 3-year CAGR, LUCY leads at 33. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -788. 2% for ProPhase Labs, Inc. — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus -570. 6% for PRPH. At the gross margin level — before operating expenses — HOLX leads at 61. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6.

4x forward P/E versus 17. 4x for Victoria's Secret & Co. — 10. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for QDEL: 57. 8% to $17. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, QDEL: -34. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LUCY (Healthcare) and PRPH (Healthcare) and VSCO (Consumer Cyclical) and QDEL (Healthcare) and HOLX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LUCY is a small-cap high-growth stock; PRPH is a small-cap quality compounder stock; VSCO is a small-cap quality compounder stock; QDEL is a small-cap quality compounder stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.